SCHEMBL6476162

SCHEMBL6476162

CCN(CC)Cc1ccc(CCCc2ccc(Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.52
PLK1 P53350 4/20 0.50
FABP4 P15090 1/20 0.50
PLK3 Q9H4B4 3/20 0.48
PTGS1 P23219 1/20 0.47
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
ABCC1 P33527 2/20 0.46
CLCN2 P51788 1/20 0.45
TRPA1 O75762 1/20 0.45
TRPM2 O94759 1/20 0.45
PLA2G1B P04054 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.45
CYSLTR2 Q9NS75 1/20 0.45
CYSLTR1 Q9Y271 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476651 0.86 MEN1 (0.51) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6474913 0.85 MEN1 (0.55) MEN1KMT2ARECQLBLMTDP1
SCHEMBL16489009 0.84 PLK1 (0.64) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475966 0.84 MEN1 (0.54) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6483326 0.84 MEN1 (0.58) MEN1KMT2ARECQLBLMTDP1
SCHEMBL22452812 0.83 FABP4 (0.50) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6476391 0.82 MEN1 (0.57) MEN1KMT2ARECQLBLMTDP1
SCHEMBL4248139 0.82 PLK1 (0.72) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6481725 0.82 MEN1 (0.62) MEN1KMT2ARECQLBLMTDP1
SCHEMBL13855746 0.82 MEN1 (0.65) MEN1KMT2ARECQLBLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885RECQL 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.